Thelansis

 Anal cancer is an uncommon malignancy that originates within the anal canal, a narrow passage at the terminal end of the rectum responsible for facilitating the expulsion of stool from the body. Notable indicators of anal cancer encompass rectal bleeding and anal discomfort. The principal risk factor for developing anal cancer is infection with the human papillomavirus (HPV), a sexually transmitted virus known to also cause warts in the vicinity of the anus or genital area in both men and women. It's noteworthy that anal cancer can manifest without the presence of warts. Other contributing factors include advancing age (55 years and older), engaging in anal intercourse, contracting sexually transmitted diseases, having multiple sexual partners, tobacco use, a history of HPV-associated cancers, particularly cervical cancer, and a weakened immune system due to conditions like HIV, chemotherapy, or organ transplantation. Besides a comprehensive patient history and physical examinatio...

  Anal cancer is a rare cancer that occurs in the anal canal. The anal canal is a small tube at the end of your rectum that allows stool to exit your body. Rectal bleeding and anal pain are two signs and symptoms of anal cancer.  The prevalence of anal cancer is about 8,590 new cases (5,900 in women and 2,690 in men) and 1,350 deaths (810 in women and 540 in men). Thelansis’s “Anal Cancer Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Anal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated...